The Impact of COVID-19 on Psychiatric Health in the Korean Population.
COVID-19
Health
Korea
Psychiatry
SARS-CoV-2
Journal
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
ISSN: 1738-1088
Titre abrégé: Clin Psychopharmacol Neurosci
Pays: Korea (South)
ID NLM: 101207332
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
08
04
2023
revised:
21
05
2023
accepted:
22
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) has multiple negative impacts on the psychiatric health of both those previously infected and not infected with severe acute respiratory syndrome coronavirus 2. Moreover, the negative impacts of COVID-19 are closely associated with geographical region, culture, medical system, and ethnic background. We summarized the evidence of the impact of COVID-19 on the psychiatric health of the Korean population. This narrative review included thirteen research articles, which investigated the impact of COVID-19 on the psychiatric health of Koreans. COVID-19 survivors were reported to have a 2.4 times greater risk of developing psychiatric disorders compared to members of a control group, and anxiety and stress-related disorders were the most common newly diagnosed psychiatric illnesses. Studies also reported that COVID-19 survivors had a 3.33-fold higher prevalence of insomnia, a 2.72-fold higher prevalence of mild cognitive impairment, and a 3.09-fold higher prevalence of dementia compared to the control group. In addition, more than four studies have highlighted that the medical staff members, including nurses and medical students, exhibit a greater negative psychiatric impact of COVID-19. However, none of the articles investigated the biological pathophysiology or mechanism linking COVID-19 and the risk of diverse psychiatric disorders. Moreover, none of the studies were actual prospective studies. Thus, longitudinal studies are needed to more clearly elucidate the effect of COVID-19 on the psychiatric health of the Korean population. Lastly, studies focusing on preventing and treating COVID-19-associated psychiatric problems are needed to provide a benefit in real clinical settings.
Identifiants
pubmed: 37424410
pii: cpn.23.1083
doi: 10.9758/cpn.23.1083
pmc: PMC10335912
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
410-418Références
N Engl J Med. 2009 May 21;360(21):2153-5, 2157
pubmed: 19423867
J Pers Med. 2021 Oct 09;11(10):
pubmed: 34683156
BJPsych Open. 2021 Oct 01;7(6):e183
pubmed: 34659793
PLoS One. 2022 Sep 12;17(9):e0273637
pubmed: 36094911
BMC Public Health. 2010 Mar 30;10:172
pubmed: 20353554
Clin Psychopharmacol Neurosci. 2021 May 31;19(2):294-302
pubmed: 33888658
PLoS One. 2022 Oct 31;17(10):e0277059
pubmed: 36315569
Sleep Med Rev. 2022 Apr;62:101591
pubmed: 35131664
SN Compr Clin Med. 2020;2(11):2037-2047
pubmed: 33083695
Front Psychiatry. 2021 Jun 22;12:642918
pubmed: 34239459
Front Psychiatry. 2021 Jul 07;12:611108
pubmed: 34305663
J Clin Sleep Med. 2021 Feb 1;17(2):299-313
pubmed: 33108269
Front Psychiatry. 2022 Jul 22;13:934202
pubmed: 35935440
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Psychiatry Res. 2022 Jul;313:114615
pubmed: 35567852
Lancet Psychiatry. 2020 Apr;7(4):e20
pubmed: 32085842
Clin Psychopharmacol Neurosci. 2022 Feb 28;20(1):97-108
pubmed: 35078952
Int J Environ Res Public Health. 2021 Jul 10;18(14):
pubmed: 34299829
Cancer Res Treat. 2022 Jul;54(3):671-679
pubmed: 34583461
Int J Psychiatry Med. 2022 Jul;57(4):323-337
pubmed: 34425688
Clin Psychopharmacol Neurosci. 2022 Feb 28;20(1):185-189
pubmed: 35078961
BJPsych Open. 2022 Sep 08;8(5):e166
pubmed: 36073010
JMIR Infodemiology. 2021 Nov 12;1(1):e32127
pubmed: 34841200
Am J Alzheimers Dis Other Demen. 2022 Jan-Dec;37:15333175211072387
pubmed: 35050807
Respirology. 2010 Apr;15(3):543-50
pubmed: 20337995
Clin Psychopharmacol Neurosci. 2022 May 31;20(2):199-210
pubmed: 35466092
Compr Psychiatry. 2009 Jul-Aug;50(4):385-90
pubmed: 19486738
PLoS One. 2022 Jul 12;17(7):e0271059
pubmed: 35819941
Neurochem Res. 2023 Apr;48(4):1015-1025
pubmed: 35922744
Psychiatry Investig. 2022 Aug;19(8):676-686
pubmed: 36059057
Crit Care Med. 2021 Sep 1;49(9):1427-1438
pubmed: 33769771
J Neuroinflammation. 2022 Sep 7;19(1):222
pubmed: 36071466
Lancet Psychiatry. 2021 Feb;8(2):87
pubmed: 33485416
BMC Public Health. 2006 Sep 14;6:230
pubmed: 16970828
Psychiatry Investig. 2021 Nov;18(11):1082-1090
pubmed: 34710959
Clin Psychopharmacol Neurosci. 2023 Feb 28;21(1):2-9
pubmed: 36700307
Cancer Cell. 2020 Aug 10;38(2):161-163
pubmed: 32710820
Scand J Work Environ Health. 2020 Nov 1;46(6):639-644
pubmed: 32905601
Int J Soc Psychiatry. 2020 Jun;66(4):317-320
pubmed: 32233719
Neuropharmacology. 2022 May 15;209:109023
pubmed: 35257690